Welcome to our dedicated page for Aimei Health Technology Co SEC filings (Ticker: AFJK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to keep pace with undefined’s rapid Special Purpose Acquisition Company milestones can feel daunting, especially when critical details hide in dozens of SEC exhibits. Our platform surfaces what matters first—whether you’re tracking undefined insider trading Form 4 transactions or waiting for the next undefined 8-K material events explained.
You’ll find every submission here, from the sparse undefined quarterly earnings report 10-Q filing that highlights trust interest, to the definitive undefined annual report 10-K simplified that lays out sponsor warrants and redemption mechanics. Stock Titan’s AI models read each paragraph in real time, turning complex legal language into plain-English bullet points and answering questions like “How much cash is left in the trust?” or “What happens if the merger deadline shifts again?” Need to monitor management activity? Set alerts for undefined executive stock transactions Form 4 and receive instant summaries of buying or selling.
Because SPAC timelines move quickly, we publish filings the moment they hit EDGAR and pair them with contextual notes—so you can review the undefined proxy statement executive compensation, compare warrant adjustments across quarters, or dissect a fresh undefined earnings report filing analysis without wading through 200 pages. From understanding undefined SEC documents with AI to auditing every undefined Form 4 insider transactions real-time, this page delivers the clarity professionals need to make informed decisions before redemption windows close.
Aimei Health Technology Co., Ltd. (AFJK) filed its quarterly report for the period ended September 30, 2025, showing it remains a pre-revenue SPAC earning income from its trust investments. The company reported net income of $352,019 for the quarter and $961,651 for the nine months, driven by $482,171 and $1,546,821 of interest on cash held in the trust account, partially offset by formation and operating costs. As of September 30, 2025, Aimei held $45,443,570 in its trust account and had a working capital deficit of about $2.75 million, with only $2,979 of cash outside the trust. During February 2025, shareholders redeemed 2,904,267 shares for approximately $31.27 million, reducing redeemable shares to 3,995,733. The company has a signed business combination agreement with United Hydrogen, which shareholders later approved, and has repeatedly extended its deadline to complete the merger to December 6, 2025 using unsecured promissory notes from its sponsor and United Hydrogen. Management notes that failure to close a business combination within the allowed period would trigger liquidation, creating substantial doubt about Aimei’s ability to continue as a going concern.
Aimei Health Technology (AFJK) reported shareholder approvals to proceed with its proposed business combination with United Hydrogen and related mergers. Shareholders also approved the issuance of approximately 157,568,133 newly issued ordinary shares in connection with the transaction, as described in the proxy materials.
The Business Combination Proposal and the Merger Proposal each passed with 70.80% of votes cast in favor (3,832,573 for; 1,580,804 against). The Share Issuance Proposal passed with 67.23% in favor (3,639,303 for; 1,774,074 against). An Adjournment Proposal also passed on the same vote totals as the Share Issuance Proposal. As of the record date on September 26, 2025, ordinary shares outstanding were 6,121,733; this is a baseline figure, not the amount being issued.
Following the approvals, 3,950,411 Public Shares were tendered for redemption. The company also outlined an extension meeting to allow more time to close if the business combination is not completed before December 6, 2025.
Aimei Health Technology (AFJK) called an Extraordinary General Meeting on November 26, 2025 to vote on four items that shape its SPAC timeline and governance. The key proposal amends Article 35.2 to extend the deadline to complete a business combination from 24 months to as late as 36 months from the IPO, moving the termination date to December 6, 2026. A related proposal would amend the Trust Agreement to reduce each monthly extension payment by the Sponsor to the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share.
If the article amendment is approved, public shareholders may elect to redeem at a per‑share amount equal to the Trust Account balance divided by Public Shares; this was approximately $11.33 per Public Share as of September 26, 2025. The redemption deadline is 5:00 p.m. ET on November 24, 2025, with delivery via DWAC or certificates. Shareholders will also vote on appointing MaloneBailey, LLP as auditor for 2025 and authorizing potential adjournment to solicit additional votes.
Aimei Health Technology (AFJK) extended its merger deadline by one month after depositing $150,000 into its trust account, moving the termination date from November 6, 2025 to December 6, 2025. This is the twelfth and final extension permitted under its articles.
To fund the deposit, AFJK issued an unsecured $150,000 promissory note on November 4, 2025 to its sponsor and United Hydrogen Group Inc., split $75,000 each. The note bears no interest and becomes due upon consummation of the proposed business combination with United Hydrogen. The payees may convert the note into private units at $10.00 per unit—each unit comprising one ordinary share and one right to receive one-fifth of one ordinary share—immediately prior to closing, with at least two business days’ written notice.
Aimei Health Technology (AFJK) filed a preliminary proxy calling an extraordinary general meeting on November 26, 2025 to vote on four proposals. The key item seeks to amend the Articles to extend the SPAC deadline from 24 months to 36 months, pushing the termination date to December 6, 2026. A related trust amendment would reduce each monthly extension payment to the lesser of $80,000 for all outstanding Public Shares or $0.033 per Public Share, payable by the Sponsor.
If the Article Amendment is approved, Public Shareholders may elect to redeem their shares for their pro rata portion of the trust. As context, the per‑share trust amount was approximately $11.33 as of September 26, 2025, and the redemption deadline is 5:00 p.m. ET on November 24, 2025. Additional proposals ask shareholders to appoint MaloneBailey, LLP as auditor for 2025 and to allow meeting adjournment if needed. The Article Amendment requires at least two‑thirds of votes cast; the other proposals require a simple majority.
Aimei Health and United Hydrogen Global Inc. have agreed to a business combination that would merge United Hydrogen into a newly renamed Pubco and convert the outstanding securities of both targets into Pubco ordinary shares. Shareholders will vote at an Extraordinary General Meeting on
The transaction is structured on a pre-money equity value of
FAQ
What is the current stock price of Aimei Health Technology Co (AFJK)?
What is the market cap of Aimei Health Technology Co (AFJK)?
